BOSTON, June 11, 2018 /PRNewswire/ — Fresenius Medical Care, the world’s largest provider of dialysis products and services, and Humacyte, Inc., a medical research, discovery and development company, today announced a strategic, global partnership and a $150M USD equity investment. This agreement has the potential to make Humacyte’s investigational human acellular vessel, HUMACYL®, available […]
Peripheral/Endo
Micro Medical Solutions Marks First U.S. Implants of MicroStent for Peripheral Artery Disease
WILMINGTON, Mass.–(BUSINESS WIRE)–Micro Medical Solutions (MMS), an innovator in the field of microvascular interventions that aim to improve clinical outcomes and quality of life, announced a major milestone today in the development of its MicroStent technology, a vascular stent specifically designed to reduce below-the-knee amputations caused by critical limb ischemia […]
Biomerics Acquires FutureMatrix Interventional
SALT LAKE CITY, June 4, 2018 /PRNewswire/ — Biomerics LLC, a medical device contract manufacturer headquartered in Salt Lake City, UT is pleased to announce the acquisition of FutureMatrix Interventional, Inc. FMI, located in Athens, TX specializes in the design and manufacture of interventional catheters for the cardiovascular and urinary markets. “We are pleased to add […]
Avinger Announces Presentations and Posters Featuring Lumivascular Technology at New Cardiovascular Horizons Annual Conference
REDWOOD CITY, Calif., May 30, 2018 (GLOBE NEWSWIRE) — Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced a schedule of sessions and posters highlighting the company’s Lumivascular technology at the New Cardiovascular Horizons (NCVH) annual conference taking place this week in New […]
Avinger to Present at the 8th Annual LD Micro Invitational
REDWOOD CITY, Calif., May 29, 2018 (GLOBE NEWSWIRE) — Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced today that it will be presenting at the 8th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel in Bel Air, California. The conference will be […]
XableCath Receives Second FDA Clearance for Its Peripheral Arterial Catheters
SALT LAKE CITY–(BUSINESS WIRE)–XableCath, Inc., innovators of products designed to aid in the treatment of peripheral artery disease (PAD), announced that its second catheter, XableCath™ abrasion tip support catheter, was cleared by the FDA. The XableCath blunt tip catheter received FDA clearance at the end of 2017. This clearance gives […]
Avinger Receives FDA Clearance of Next Generation Pantheris Device
REDWOOD CITY, Calif., May 23, 2018 (GLOBE NEWSWIRE) — Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced today that the Company received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for its next generation Pantheris® Lumivascular atherectomy system, the first-ever image-guided […]
FlowTriever System from Inari Medical Receives FDA 510(k) Clearance for Treatment of Pulmonary Embolism
IRVINE, Calif., May 21, 2018 /PRNewswire/ — Inari Medical, Inc., announced today the FlowTriever System has received FDA 510(k) clearance for the treatment of pulmonary embolism (“PE”). This clearance makes the FlowTriever System the first and only thrombectomy device cleared by the FDA for the treatment of PE. The PE-specific clearance was based […]
The Modernization of Carotid Repair to Reduce the Risk of Stroke
Contributed by Steve Henao, MD A very pleasant, active 75-year-old patient at our hospital received the disturbing news last July that she had an 80 percent blockage in one of her two carotid arteries, a diagnosis known as carotid artery disease. She was concerned about the risk of treatment and […]
Amgen Receives European Commission Approval For Repatha® (Evolocumab) To Prevent Heart Attack And Stroke In Adults With Established Cardiovascular Disease
THOUSAND OAKS, Calif., May 16, 2018 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced that the European Commission (EC) has approved a new indication in the Repatha® (evolocumab) label for adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering low-density lipoprotein cholesterol (LDL-C) levels. With the […]



